Responsible for the design, development, implementation, and evaluation of for-credit and non-credit professional educational programs and services in the areas of healthcare and drug development. Offer career development opportunities to pharmacists, pharmaceutical professionals, managers, and government agencies worldwide. Collaborate with internal and external business partners to facilitate world-class professional continuing education programs.

Experience

Leslie joined the Division of Pharmacy Professional Development in August 2019.  She has thirteen years of experience in drug discovery and development working at both Amgen and Genentech/Roche.  Her areas of expertise include drug metabolism and pharmacokinetics, pharmacogenomics, drug-drug interactions, ocular and oncology drug development and patient-centric clinical trial design.  

Skills

• In-depth understanding of drug discovery and development from lead compound to marketing authorization  
• Communicating and messaging complex scientific data
• Championing academic and industry collaborations
• Innovating clinical trial design and using novel technologies on clinical trials
• Preclinical and clinical PKPD strategy development for small molecules, protein therapeutics and novel delivery systems 
• Utilizing pharmacogenomics to advance personalized healthcare  
• Preparation of regulatory documents (IND, NDA/BLA and PIP/PSP) 
• Comprehensive knowledge of immunology, cancer and ophthalmology drug development  
• In-depth knowledge of biomarker development and companion diagnostics  

Education

• BS in Molecular Biology, University of Wisconsin - Madison
• PhD in Medicinal Chemistry, University of Washington
• MPH in Applied Epidemiology, Emory University

Current experience

• PHM SCI 762 - The Drug Development Process I: Discovery to IND (3 credits, Fall)
• PHM SCI 763 - The Drug Development Process II: FIH to NDA/BLA (3 credits, Spring and Fall)
• PHM SCI 755 - Laboratory and Instrumentation Methods (3 credits, Spring)
• PHM SCI 759 - Current Trends in Drug Discovery and Development (1 credit, Spring and Fall)
• PHM SCI 757 - Survey of the Neuroactive Drug Development Process (2 credits, Spring and Fall)
• PHARMACY 801 - Bioethics and Scientific Integrity (2 credits, Spring and Fall)
• Guest lecturer - University of Washington, Pharmaceutics and Medicinal Chemistry graduate programs

Previous experience

• Mentor - Genentech Gene Academy
• Teaching Assistant - South San Francisco High School Science Garage

• Dickmann LJ and Kothare PA.  Can digital health enable higher quality real-world evidence-based decisions? Clin Pharmacol Ther 2019 Jul; 106(1):45-46.
• Loyet KM, Hass PE, Sandoval WN, Morando A, Liu P, Shatz W, Dickmann L, Kenrick M, Good J, Davancaze T, Morimoto AM, Kelley RF, Scheer JM. In vivo stability profiles of anti-factor D molecules support long-acting delivery approaches.  Mol Pharm 2019 Jan; 16(1):86-95.
• Kothare PA, Jadhav PR, Gupta P, Harrelson JC, Dickmann L.  Harnessing the potential of emerging digital health and biological sampling technologies for clinical drug development: promise to reality. Clin Pharmacol Ther 2018 Dec 104(6): 1125-1135.
• Dickmann LJ and Schutzman JL.  Racial and ethnic composition of cancer clinical drug trial: how diverse are we? Oncologist 2018 Feb; 23(2): 243-246. 
• Tesar D, Luoma J, Wyatt EA, Shi C, Shatz W, Hass PE, Mathieu M, Yi L, Corn JE, Maass KF, Wang K, Dion MZ, Andersen N, Loyet KM, van Lookeren Campagne M, Rajagopal K, Dickmann L, Scheer JM, Kelly RF.  Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.  MAbs 2017 Nov/Dec; 9(8):1297-1305. 
• Dickmann LJ and Ware JA.  Pharmacogenomics in the age of personalized medicine.  Drug Discov Today Technol 2016 Sep-Dec; 21-22:11-16. 
• Dickmann L.  Ocular therapeutics: drug delivery and pharmacology.  Mol Pharm 2016 Sep; 13(9): 2875-6. 
• Shatz W, Hass PE, Mathieu M, Kim HS, Leach K, Zhou M, Crawford Y, Shen A, Wang K, Chang DP, Maia M, Crowell SR, Dickmann L, Scheer JM, Kelley RF.  Contribution of antibody hydrodynamic size to vitreal clearance revealed through rabbit studies using a species-matched Fab.  Mol Pharm 2016 Sep; 13(9):2996-3003. 
• Wei X, Kenny J, Dickmann L, Romeo M, Looney C, and Tang M.  Assesment of disease related therapeutic protein drug-drug interation for etrolizumab in patients with moderately to severly active ulcerative colitis.  J Clin Pharmacol 2016 Jun; 56(6): 693-704. 
• Dickmann LJ, Yip V, Li C, Abundes J, Maia M, Young C, Stainton S, Hass PE, Josesph SB, Prabhu S, and Boswell CA.  Evaluation of fluorophotometry to assess vitreal pharmacokinetics of protein therapeutics.  Invest Ophthalmol Vis Sci 2015 Oct; 56(11):6991-9. 
• Wang Z, Wong T, Hashizume T, Dickmann L, Scian M, Koszewski N, Goff J, Horst R, Chaudhry A, Schuetz E, Thummel K.  Human UGT1A4 and UGT1A3 conjugate 25-hydroxvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability. Endocrinology 2014 Jun; 155(6):2052-63. 
• Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang LK.  Critical review of preclinical approaches to investigate cytochrome P450 mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metab Dispos 2013; Sep 41(9):1598-609. 
• Wang Z, Lin YS, Dickmann LJ, Poulton EJ, Eaton DL, Lampe JW, Shen DD, Davis CL, Shuhart MC, Thummel KE.  Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. J Bone Miner Res 2013 May; 28(5): 1101-16. 
• Dickmann LJ and Isoherranen N.  Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy.  Drug Metab Dispos 2013; Feb 41(2):270-4.  
• Dickmann LJ, VandenBrink BM, Lin YS. In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic characteristics.  Drug Metab Dispos 2012; Jul 40(7) 1263-7. 
• Dickmann LJ, McBride HJ, Patel SK, Miner K, Wienkers LC, Slatter JG.  Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression.  Biochem Pharmacol 2012 Jun; 83(12): 1682-9. 
• Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE.  An inducible cytochrome P450 3A4 –dependent vitamin D catabolic pathway.  Mol Pharmacol 2012 Apr; 81(4): 498-509. 
• Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 2011 Aug; 39(8):1415-22. 
• Tay S, Dickmann L, Dixit V, Isoherranen N. A comparison of the peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation. Mol Pharmacol 2010 Feb; 77(2):218-27. 
• Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochem Pharmacol  2009 Jan; 77(2):258-68. 
• Dickmann LJ, Senn TD, Tay S, Unadkat JD, Hebert MF, Isoherranen N.  Changes in rat  maternal Cyp2c and Cyp2d expression and activity during pregnancy. Biochem Pharmacol  2008 Apr; 75(8):1677-1678. 
• Ribes V, Otto DM, Dickmann LJ, Schmidt K, Schuhbaur B, Henderson C, Blomhoff R, Wolf CR, Tickle C, Dolle P.  Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis.  Dev Biol 2007 Mar; 303(1):66-81. 
• Dickmann LJ, Locuson CW, Jones JP, Rettie AE. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol 2004 Apr; 65(4):842-50.  
• Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. CYP2C9 genetic polymorphisms and warfarin. Clin Appl Thromb Hemost 2004 Apr; 10(2):149-54.  
• Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001 Aug; 60(2):382-7. 
• Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr. Effect of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 2001 Jul; 41(7):715-22.